QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
August 16, 2023 08:00 ET
|
QSAM Biosciences Inc.
AUSTIN, Texas, Aug. 16, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Adds the Nuclear Reactor at the University of Texas at Austin to its Radioisotope Production Supply Chain for its Bone Cancer Treatment Drug Candidate, CycloSam®
June 14, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, June 14, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals for the...
QSAM Biosciences and RLS Announce Clinical and Commercial Supply Agreement for Promising Clinical-Stage Metastatic and Primary Bone Cancer Treatment, CycloSam®
May 16, 2023 08:30 ET
|
QSAM Biosciences Inc.
Partnership is Latest in Series of RLS Efforts to Expand Industry-Leading CDMO Business and Clinical Trial Capability with Radiopharmaceutical Partners Across U.S. Austin, TX and Lake Zurich, IL,...
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
April 26, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 26, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
April 05, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 05, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences to Provide Updates on its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023
March 20, 2023 08:30 ET
|
QSAM Biosciences Inc.
QSAM invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. Austin, TX, March 20,...
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
March 08, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, March 08, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Provides 2022 Update and 2023 Milestones to Shareholders
January 10, 2023 07:00 ET
|
QSAM Biosciences Inc.
AUSTIN, Texas, Jan. 10, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 15, 2022 08:00 ET
|
QSAM Biosciences Inc.
Further Progress Demonstrated in Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Nov. 15, 2022 (GLOBE...
QSAM Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 16, 2022 08:00 ET
|
QSAM Biosciences Inc.
Progress Shown in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- QSAM...